A new study now finds that fish oil does not appear to improve asthma control in adolescents and young adults who are overweight or obese.
The study was published online in the Annals of the American Thoracic Society.
In 'Fish Oil Supplementation in Overweight/Obese Patients with Uncontrolled Asthma: A Randomized Trial,' Jason E Lang and co-authors report that four grams of fish oil a day for six months did not improve asthma control, as measured by a standard asthma control questionnaire, breathing tests, urgent care visits and severe asthma exacerbations.
"We don't know why asthma control in obese patients is more difficult, but there is growing evidence that obesity causes systemic inflammation," said lead author of the study, Dr. Lang, adding, "Because the omega-3 fatty acids in fish oil have anti-inflammatory properties, we wanted to test whether fish oil would have therapeutic benefits for these patients."
The participants in the study were all diagnosed with asthma by a physician but had poor asthma control, despite using a daily inhaled corticosteroid to control their condition. About half the participants were African American. For every three participants assigned to take fish oil for 25 weeks, one was assigned to take the soy oil placebo.
The researchers also looked at whether a variant in the gene ALOX5 affected study findings. It is known that mutations in the gene can reduce responses to anti-leukotriene drugs. In the study, the ALOX5 variant did appear to be linked to leukotriene production but not to the effectiveness of fish oil in providing asthma control.
According to the authors, the study's negative findings may not be the last word on fish oil and asthma. They acknowledged that larger doses of fish oil over a longer period of time may produce a different result.
Dr Lang, however, concluded that based on the current study, "there is insufficient evidence for clinicians to suggest to patients with uncontrolled asthma that they should take daily fish oil supplements to help their asthma.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
